



OPEN ACCESS

EDITED AND REVIEWED BY
Zhi-Gang Zhang,
Shanghai Jiao Tong University, China

*CORRESPONDENCE
Shudong Zhu,
✉ 1125537080@qq.com

RECEIVED 07 July 2023
ACCEPTED 14 July 2023
PUBLISHED 19 July 2023

CITATION
Zhu S and Zhang D (2023), Editorial:
Regulation and dysfunction of CSK
and CHK.
Front. Cell Dev. Biol. 11:1254961.
doi: 10.3389/fcell.2023.1254961

COPYRIGHT
© 2023 Zhu and Zhang. This is an open-
access article distributed under the terms
of the [Creative Commons Attribution
License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is
permitted, provided the original author(s)
and the copyright owner(s) are credited
and that the original publication in this
journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Editorial: Regulation and dysfunction of CSK and CHK

Shudong Zhu^{1*} and Dianzheng Zhang²

¹School of Medicine, Nantong University, Nantong, China, ²Department of Bio-Medical Sciences, Philadelphia College of Osteopathic Medicine, Philadelphia, PA, United States

KEYWORDS

Csk, Chk, structure, regulation, target, function, apoptosis, integrin

Editorial on the Research Topic Regulation and dysfunction of CSK and CHK

The Src family kinases (SFKs) play indispensable roles in multiple signal transduction pathways. SFKs are activated by autophosphorylation (human Src: Tyr419) in the trans-molecular mode and abnormal SFK activation often leads to cancer and other diseases. C-terminal Src kinase (CSK) phosphorylates SFKs at their C-terminal tyrosine and inactivates SFKs. CSK homologous kinase (CHK) shares same SH2-SH3-SH1 structure and 53% amino acid identity with CSK. There is evidence suggesting CSK may be a dominant player in contrast to an auxiliary role of CHK in certain tissue or cells (Nagy et al., 2020). A unique feature of CHK is that it inactivates SFKs via a non-catalytic mechanism. The recent discovery of CHK promoter hypermethylation-promoted colon cancer supports the notion that dysfunction of CSK/CHK is involved in pathogenesis (Zhu et al., 2021). Although studies have shown that dysregulation of CHK and CSK is present in diseases other than cancers, the underlying mechanisms remain unknown. Moreover, increasing evidence indicates that CHK and CSK are not functionally redundant and likely intertwined with each other in disease development. Recent research suggests that in addition to the CHK/CSK-SFK axis, CHK and CSK likely to be involved in pathways with some novel targets and modes of regulation.

This Research Topic “*Regulation and Dysfunction of CSK and CHK*” consists of 5 review articles contributed by 17 authors in the fields of CSK and CHK. The Research Topic collects different research aspects including molecular structures of CSK and CHK, major signaling pathways such as apoptosis and integrin signaling in cancers affected by CSK and CHK and comprehensive overviews of CSK and CHK highlighting their regulation, molecular targets and functional roles.

In addition to the general features of phosphorylating substrates, CSK and CHK have unique structural motifs determining their substrate specificity and enzymatic efficiencies. CSK and CHK are also subject to regulation by different regulators and/or post-translational modifications. To understand the roles of CSK and CHK and their functional differences in inactivating SFKs, Sun et al. have reviewed the structure-function relationship of CSK and CHK with an emphasis on catalysis, substrate recognition, and the interactions between domain and domain/key phosphorylation site. This review not only summarizes the current understanding of CSK/CHK enzymology but also sheds light on the general mechanism of regulation and catalysis of protein tyrosine kinases. This will be helpful in bolstering protein phosphorylation as a key methodology for the development of anti-cancer therapeutics.

Apoptosis, a form of programmed cell death, plays a key role in multiple biological processes (Capela E Silva and Rodrigues, 2023). The extrinsic pathway is initiated through

activation of death receptors (such as Fas, DR4, DR5) engaged by their ligands (such as FasL and Apo2L/TRAIL) which ultimately triggers the activation of caspase 8. The intrinsic pathway is initiated through the activation of the Bcl-2 family of pro-apoptotic proteins such as Bax/Bak in response to pro-apoptotic stimuli. Activation of Bax/Bak leads to increased permeability of the mitochondrial membrane and eventually the activation of effector caspases. These cysteine-aspartic proteases subsequently cleave proteins resulting in cellular demise. Fortner et al. provide an overview of the apoptosis mechanisms induced by CSK. CSK suppresses MAPK, STAT3 and PI3K signaling respectively, all of which are involved in promoting cell survival through upregulation of pro-survival molecules such as Myc and Bcl-2, and downregulation of pro-apoptotic molecules such as Bim and FOXO. The Src-dependent pro-apoptotic effect of CSK has been further confirmed by a novel Src inhibitor (Abdelall et al., 2022). Therefore, targeting key molecules in these pathways to promote apoptosis could be a strategy in the development of potential treatment of diseases such as cancer (Tang et al., 2023).

As a part of the focal adhesion, integrins can sense and send extracellular signals to the cytosol to regulate different processes such as cell migration, invasion, proliferation, and survival. Therefore, integrins play crucial roles in cancer progression and metastasis. Maldonado et al. reviewed how CSK regulates integrin signaling through SFKs. These authors focus on the crucial role of integrins in sensing and responding to mechanical changes in the surrounding environment by emphasizing their mechanosensing and mechanotransduction functions (Hamidi and Ivaska, 2018; Koudelková et al., 2021). They have also discussed the crosstalk among CSK, integrins, and growth factor receptors suggesting that they could become potential therapeutic targets.

Besides the above specific Research Topic focuses, Zhu et al. have provided overviews of how CSK and CHK are regulated, their molecular targets, and novel biological functions involved. Among many interesting new features of CSK/CHK, it is noteworthy that CHK not only phosphorylates SFKs to inactivate them, CHK also serves as a non-enzymatic inhibitor for many Src family members; Unlike CSK which is expressed ubiquitously, expression of CHK is limited in several tissues; Novel targets of CHK including SHPS-1, paxillin, and synuclein have been identified. Therefore, CHK may complement or strengthen CSK's effect in inhibiting SFKs in certain tissues. CHK silencing due to DNA methylation (Chüeh et al., 2021; Zhu et al., 2021) in certain cancer types suggests that CHK epigenetics could serve as a therapeutic or diagnostic candidate. On the other hand, in addition to the established CSK-SFK axis, the recent discoveries of novel CSK targets such as MITA (Gao et al., 2020) and novel regulators of CSK such as SPOP (Tawaratsumida

et al., 2022), and the unveiled pathology of many diseases newly reported to be associated with CSK warrant further exploration of CSK.

In conclusion, the "Regulation and Dysfunction of CSK and CHK" Research Topic highlights the recent discoveries of molecular structure, targets, regulation and biological function of CSK/CHK. This not only furthered our understanding in basic research but also paved the way for the development of new therapies and diagnosis.

Author contributions

SZ and DZ made substantial and direct contribution to this work. All authors contributed to the article and approved the submitted version.

Funding

This work was supported in part by NTU University (SZ, NTU03083068).

Acknowledgments

We thank the editors for their support. We thank all contributing authors and reviewers for their contribution to this Research Topic. We thank Kamakshi Ranjan for editing of the manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

- Abdelall, E. K. A., Elshemy, A. H. H., Labib, M. B., and E A Mohamed, F. (2022). Characterization of novel heterocyclic compounds based on 4-aryl-4H-chromene scaffold as anticancer agents: Design, synthesis, antiproliferative activity against resistant cancer cells, dual β -tubulin/c-Src inhibition, cell cycle arrest and apoptosis induction. *Bioorg. Chem.* 120, 105591. doi:10.1016/j.bioorg.2021.105591
- Capela E Silva, F., and Rodrigues, C. M. P. (2023). Apoptosis-50 Years after its discovery. *Biomedicines* 11 (4), 1196. doi:10.3390/biomedicines11041196
- Chüeh, A. C., Advani, G., Foroutan, M., Smith, J., Ng, N., Nandurkar, H., et al. (2021). CSK-homologous kinase (CHK/MATK) is a potential colorectal cancer tumour suppressor gene epigenetically silenced by promoter methylation. *Oncogene* 40 (17), 3015–3029. doi:10.1038/s41388-021-01755-z
- Gao, P., Hu, M. M., and Shu, H. B. (2020). CSK promotes innate immune response to DNA virus by phosphorylating MITA. *Biochem. Biophys. Res. Commun.* 526 (1), 199–205. doi:10.1016/j.bbrc.2020.03.069
- Hamidi, H., and Ivaska, J. (2018). Every step of the way: Integrins in cancer progression and metastasis. *Nat. Rev. Cancer* 18 (9), 533–548. doi:10.1038/s41568-018-0038-z
- Koudelková, L., Brábek, J., and Rosel, D. (2021). Src kinase: Key effector in mechanosignalling. *Int. J. Biochem. Cell Biol.* 131, 105908. doi:10.1016/j.ijbc.2020.105908

- Li, P., Dong, X. R., Zhang, B., Zhang, X. T., Liu, J. Z., Ma, D. S., et al. (2021). Molecular mechanism and therapeutic targeting of necrosis, apoptosis, pyroptosis, and autophagy in cardiovascular disease. *Chin. Med. J.* 134, 2647–2655. doi:10.1097/CM9.0000000000001772
- Nagy, Z., Mori, J., Ivanova, V. S., Mazharian, A., and Senis, Y. A. (2020). Interplay between the tyrosine kinases Chk and Csk and phosphatase PTPRJ is critical for regulating platelets in mice. *Blood* 135 (18), 1574–1587. doi:10.1182/blood.2019002848
- Tang, Y., Wang, L., Qin, J., Lu, Y., Shen, H. M., and Chen, H. B. (2023). Targeting mitophagy to promote apoptosis is a potential therapeutic strategy for cancer. *Autophagy* 19 (3), 1031–1033. doi:10.1080/15548627.2022.2112830
- Tawaratsumida, K., Redecke, V., Wu, R., Kuriakose, J., Bouchard, J. J., Mittag, T., et al. (2022). A phospho-tyrosine-based signaling module using SPOP, CSK, and LYN controls TLR-induced IRF activity. *Sci. Adv.* 8 (27), eabq0084. doi:10.1126/sciadv.abq0084
- Zhu, S., Zhu, Y., Wang, Q., Zhang, Y., and Guo, X. (2021). CHK methylation is elevated in colon cancer cells and contributes to the oncogenic properties. *Front. Cell Dev. Biol.* 9, 708038. doi:10.3389/fcell.2021.708038